PRESS RELEASE
Notable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer
Industry Dealmaker Joins Notable to Accelerate In-licensing Strategy to Fuel Predictive Precision Platform and Pipeline
Industry Dealmaker Joins Notable to Accelerate In-licensing Strategy to Fuel Predictive Precision Platform and Pipeline
News
NEW YORK – Notable, a Bay Area firm using automated laboratory testing, artificial intelligence, and single-cell omics for cancer drug discovery, said yesterday that it has raised $40 million in a Series B financing round to accelerate the development of its services.
The financing was co-led by B Capital Group and returning investor LifeForce Capital. Industry Ventures also participated in the round, which brings Notable’s total funding to more than $55 million.
Loading...